China is Australia’s largest trading partner – worth $8.8 billion in 2014-2015. China and Australia are also growing partners in science and research and this is an important area for growth in bilateral relations. China is and has been Australia’s key focus for science and research collaboration efforts; generating advances in medical research, biodiversity, net […]
Read More
The World Health Organization states that cardiovascular disease (CVD) has been the number one global cause of death; with an estimation of 17.5 million people dying from CVD in 20121, representing 31% of all global deaths. CVD has been and is currently the major cause of death in Australia2 accounting for over 43,600 deaths in […]
Read More
Over the past years, the number of mobile phone subscribers in China has been increasing at an exponential rate. By the end of 2015, there was approximately 202.47 million cell phones produced in China1 along with 1,033.6 million mobile users registered in China, with the number of users expected to grow to 1,086.8 by 2019. […]
Read More
George Clinical (GC) conducted a brief survey on sponsors who are currently not a customer of GC. 30 companies were surveyed by GC’s Business Development Managers across six countries which included the United States, China, Australia, Korea, United Kingdom and Israel. The primary objective of the survey was to determine the services and countries that were important […]
Read More
Sulfagenix, Inc., a United States based biotech, was able to tap into Australia’s world class research and development (R&D) facilities and expertise
Read More
Chronic obstructive pulmonary disorder (COPD) is now the third most frequent cause of death in the world; however the cause of this disease for a substantial proportion of patients remains unknown.
Read More
George Clinical is an Australian owned organization headquartered in Sydney, Australia. In Sydney, we are co-located with our partner in research, The George Institute, a world leading medical research institute. From this location, we oversee our operations throughout Asia-Pacific. Australia is an attractive place to conduct clinical research with an efficient regulatory process, highly experienced […]
Read More
